4//SEC Filing
Woock John 4
Accession 0001562180-23-000520
CIK 0001603756other
Filed
Jan 18, 7:00 PM ET
Accepted
Jan 19, 8:07 PM ET
Size
26.4 KB
Accession
0001562180-23-000520
Insider Transaction Report
Form 4
Axonics, Inc.AXNX
Woock John
Chief Marketing Officer
Transactions
- Sale
Common Stock
2023-01-17$67.62/sh−2,793$188,855→ 45,976 total - Exercise/Conversion
Common Stock
2023-01-17$1.42/sh+378$537→ 46,354 total - Sale
Common Stock
2023-01-17$67.29/sh−15,000$1,009,385→ 45,976 total - Exercise/Conversion
Stock Options (Right to buy)
2023-01-17−12,044→ 3,581 totalExercise: $25.82Exp: 2029-12-12→ Common Stock (12,044 underlying) - Exercise/Conversion
Common Stock
2023-01-17$1.32/sh+2,793$3,687→ 48,769 total - Exercise/Conversion
Common Stock
2023-01-17$25.82/sh+12,044$310,976→ 58,020 total - Sale
Common Stock
2023-01-17$67.51/sh−378$25,519→ 45,976 total - Exercise/Conversion
Common Stock
2023-01-17$14.19/sh+15,000$212,850→ 60,976 total - Exercise/Conversion
Stock Options (Right to buy)
2023-01-17−15,000→ 15,555 totalExercise: $14.19Exp: 2029-01-30→ Common Stock (15,000 underlying) - Sale
Common Stock
2023-01-17$67.32/sh−12,044$810,772→ 45,976 total - Exercise/Conversion
Stock Options (Right to buy)
2023-01-17−378→ 0 totalExercise: $1.42Exp: 2027-08-25→ Common Stock (378 underlying) - Exercise/Conversion
Stock Options (Right to buy)
2023-01-17−2,793→ 0 totalExercise: $1.32Exp: 2027-07-05→ Common Stock (2,793 underlying)
Footnotes (5)
- [F1]This transaction was executed in multiple trades at prices ranging from $67.17 to $67.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vested on December 12, 2020 and the remainder vest at a rate of 1/36th per month commencing on January 1, 2021, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.
- [F3]The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vested on January 30, 2020, and the remainder vest at a rate of 1/36th per month commencing on February 1, 2020, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.
- [F4]The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vested on August 25, 2018 and the remainder vest at a rate of 1/36th per month commencing on September 1, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.
- [F5]The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vested on July 5, 2018 and the remainder vest at a rate of 1/36th per month commencing on August 1, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.
Documents
Issuer
Axonics, Inc.
CIK 0001603756
Entity typeother
Related Parties
1- filerCIK 0001756437
Filing Metadata
- Form type
- 4
- Filed
- Jan 18, 7:00 PM ET
- Accepted
- Jan 19, 8:07 PM ET
- Size
- 26.4 KB